FMP
Oyster Point Pharma, Inc.
OYST
NASDAQ
Inactive Equity
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
11.17 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Dr. Jeffrey Nau
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
CIK
0001720725
ISIN
US69242L1061
CUSIP
69242L106
Address
202 Carnegie Ctr Ste 109
Phone
16093829032
Country
US
Employee
303
IPO Date
Oct 31, 2019
Financial Statement
Earnings
OYST Financial Summary
CIK
0001720725
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
69242L106
ISIN
US69242L1061
Country
US
Price
11.17
Beta
0
Volume Avg.
417.56k
Market Cap
0
Shares
-
52-Week
3.46-13.45
DCF
18.58
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.oysterpointrx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest OYST News
Zacks Investment Research
Nov 10, 2022
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimat...
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse2
Nov 7, 2022
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.
GlobeNewsWire
Nov 2, 2022
Oyster Point Pharma To Report Third Quarter 2022 Financial R...
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
GlobeNewsWire
Sep 27, 2022
Oyster Point Pharma to Present New Scientific Analyses at Wo...
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research
GlobeNewsWire
Aug 25, 2022
Oyster Point Pharma to Present Analyses at the Women in Opht...
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.
Seeking Alpha
Aug 13, 2022
Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2...
Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Oper...
Zacks Investment Research
Aug 11, 2022
OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimat...
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Aug 8, 2022
Oyster Point Pharma To Report Second Quarter 2022 Financial ...
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET
